Skip to main content

Coherus BioSciences, Inc. (CHRS)

NASDAQ: CHRS · IEX Real-Time Price · USD
17.03
-0.03 (-0.18%)
After-hours:Sep 22, 2021 5:29 PM EDT
17.06
-0.20 (-1.16%)
At close: Sep 22, 4:00 PM
Market Cap1.32B
Revenue (ttm)394.65M
Net Income (ttm)-165.21M
Shares Out75.56M
EPS (ttm)-2.29
PE Ration/a
Forward PE32.89
Dividendn/a
Ex-Dividend Daten/a
Volume526,431
Open17.30
Previous Close17.26
Day's Range17.03 - 17.44
52-Week Range12.21 - 22.22
Beta1.02
AnalystsBuy
Price Target25.71 (+50.7%)
Est. Earnings DateNov 4, 2021

About CHRS

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimuma...

IndustryBiotechnology
IPO DateNov 6, 2014
CEODennis Lanfear
Employees311
Stock ExchangeNASDAQ
Ticker SymbolCHRS
Full Company Profile

Financial Performance

In 2020, CHRS's revenue was $475.82 million, an increase of 33.63% compared to the previous year's $356.07 million. Earnings were $132.24 million, an increase of 47.21%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is 25.71, which is an increase of 50.70% from the latest price.

Price Target
$25.71
(50.70% upside)
Analyst Consensus: Buy

News

Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

REDWOOD CITY, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright Globa...

1 week ago - GlobeNewsWire

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Aug. 26, 2021, the compensation committee of ...

3 weeks ago - GlobeNewsWire

New Strong Sell Stocks for August 25th

BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021

Other symbols:BEEMKMDAPHUNSTIM
4 weeks ago - Zacks Investment Research

Coherus (CHRS), Junshi Announce Positive NSCLC Study Results

Coherus BioSciences (CHRS) and partner Junshi announce positive data from a late-stage study on toripalimab for the first-line treatment of NSCLC.

1 month ago - Zacks Investment Research

Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating To...

– Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone –

1 month ago - GlobeNewsWire

New Strong Sell Stocks for August 17th

ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.

Other symbols:ACCDELVTFLGTGSHD
1 month ago - Zacks Investment Research

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -60.00% and 6.05%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th

REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market ...

1 month ago - GlobeNewsWire

Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

- Csiki has over two decades of experience in research and drug development of cancer immunotherapies - - Csiki has over two decades of experience in research and drug development of cancer immunotherap...

2 months ago - GlobeNewsWire

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 6, 2021, the compensation committee of t...

2 months ago - GlobeNewsWire

Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) have announced positive results from the pivotal Phase 3 JUPITER-02 trial evaluating toripalimab plus chemotherapy for the f...

3 months ago - Benzinga

Coherus BioSciences to Present at the Bank of America Health Care Conference

REDWOOD CITY, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Car...

4 months ago - GlobeNewsWire

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -2733.33% and -15.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Coherus BioSciences: Q1 Earnings Insights

Shares of Coherus BioSciences (NASDAQ:CHRS) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 97.92% year over year to $0.01, which ...

4 months ago - Benzinga

Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th

REDWOOD CITY, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be relea...

4 months ago - GlobeNewsWire

Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim...

REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring...

4 months ago - GlobeNewsWire

Blade Therapeutics Announces Appointment of Jean-Frédéric Viret as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Blade--Blade Therapeutics announces the appointment of Jean-Frédéric Viret, Ph.D., as Chief Financial Officer (CFO) effective immediately.

6 months ago - Business Wire

3 Undervalued Biotechs Worth Adding to Your Watch List

Their recent struggles may soon give way to rising market interest and more lucrative returns.

Other symbols:IRWDSUPN
6 months ago - The Motley Fool

Coherus Management to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in ...

6 months ago - GlobeNewsWire

Coherus BioSciences (CHRS) Misses Q4 Earnings and Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -52.00% and -3.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results

- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 -  - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with firs...

6 months ago - GlobeNewsWire

Earnings Preview: Coherus BioSciences (CHRS) Q4 Earnings Expected to Decline

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

CHRS or ILMN: Which Is the Better Value Stock Right Now?

CHRS vs. ILMN: Which Stock Is the Better Value Option?

Other symbols:ILMN
7 months ago - Zacks Investment Research